Peter Cuthbertson

Wollongong, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Use of Human Chronic Myeloid Leukemia Cells to Study Graft-Versus-Leukemia Immunity in a Xenogeneic Mouse Model of Graft-Versus-Host Disease.

Use of Human Chronic Myeloid Leukemia Cells to Study Graft-Versus-Leukemia Immunity in a Xenogeneic Mouse Model of Graft-Versus-Host Disease.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: March 18, 2025

Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.

Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.

Journal: International journal of molecular sciences

Published: November 28, 2023

Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice.

Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice.

Journal: Clinical & translational immunology

Published: November 21, 2023

A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice.

A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice.

Journal: Pharmaceutics

Published: July 13, 2023

Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide.

Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide.

Journal: Immunology and cell biology

Published: December 14, 2022

Purinergic signalling in graft-versus-host disease.

Purinergic signalling in graft-versus-host disease.

Journal: Current opinion in pharmacology

Published: September 12, 2022

6-Furopyridine Hexamethylene Amiloride Is a Non-Selective P2X7 Receptor Antagonist.

6-Furopyridine Hexamethylene Amiloride Is a Non-Selective P2X7 Receptor Antagonist.

Journal: Biomolecules

Published: August 09, 2022

Preparation of the Murine Anti-Human P2X7 Receptor Monoclonal Antibody (Clone L4).

Preparation of the Murine Anti-Human P2X7 Receptor Monoclonal Antibody (Clone L4).

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 01, 2022

Humanized Mouse Model to Study the P2X7 Receptor in Graft-Versus-Host Disease.

Humanized Mouse Model to Study the P2X7 Receptor in Graft-Versus-Host Disease.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 01, 2022

Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Journal: Bioscience reports

Published: June 30, 2022

The P2X7 receptor is a target of p53 and regulates haematopoiesis following radiation-induced genotoxic stress.

The P2X7 receptor is a target of p53 and regulates haematopoiesis following radiation-induced genotoxic stress.

Journal: Purinergic signalling

Published: November 30, 2021

Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease.

Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease.

Journal: International journal of molecular sciences

Published: July 13, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026